There is increasing evidence that KRAS mutation determines metformin sensitivity in mCRC by intracellular accumulation through silencing MATE1 (multidrug and toxin extrusion protein 1), with the median overall survival time for patients with diabetes on metformin treatment being 17.5 months longer than that of mCRC patients without diabetes [12]. Here, KRAS is linked to diabetes mellitus.